Top Five Articles on 360Dx Last Week: Mobile Phlebotomy Company Fraud; Quest, Agilent Deal; and More
Last week, readers were most interested in a guilty plea by a mobile phlebotomy company alleged to have engaged in a $7.5 million scheme.
Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test
The firms will develop the NGS-based CDx for non-small cell lung cancer drug Tagrisso using the Oncomine Dx Express Test on the Genexus Dx System.
Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug
The companies forged a multi-year partnership in 2018 to develop blood-based companion diagnostic tests for drugs in AstraZeneca's oncology portfolio.
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients
The test is intended to identify metastatic breast cancer patients with low HER2 expression who could benefit from treatment with Enhertu.
Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2
The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.